Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Roxann Shapiro"'
Autor:
Mark A. Socinski, Cornelius F. Waller, Tazeen Idris, Igor Bondarenko, Alexander Luft, Katrin Beckmann, Ashwini Vishweswaramurthy, Subramanian Loganathan, Charles Donnelly, Matthew A. Hummel, Roxann Shapiro, Melody Woods, Anita Rao, Vivek G Nayak, Gopinath Ranganna, Abhijit Barve
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien
Externí odkaz:
https://doaj.org/article/c16131d828264fbc8bb2cf1ee253522f
Autor:
Thomas C, Blevins, Yaron, Raiter, Bin, Sun, Charles, Donnelly, Roxann, Shapiro, Anoop, Chullikana, Anita, Rao, Laxmikant, Vashishta, Gopinath, Ranganna, Abhijit, Barve
Publikováno v:
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 36(6)
MYL-1601D is a proposed biosimilar of originator insulin aspart, NovologThis study assessed the immunogenicity, efficacy, and safety of MYL-1601D with Ref-InsAsp-US in patients with type 1 diabetes mellitus (T1D).This was a 24-week, open-label, rando
Autor:
Gopinath Ranganna, Yaron Raiter, Roxann Shapiro, Bin Sun, Thomas Blevins, Charles Donnelly, Laxmikant Vashishta, Anoop Chullikana, Anita U. Rao, Abhijit Barve
Publikováno v:
Diabetes. 70
MYL-1601D is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing Pichia pastoris yeast. This was a randomized, multicenter, open-label, parallel-group study to compare the safety and efficacy of MYL-1601D with NovoLog
Autor:
Cornelius F. Waller, Mark A. Socinski, Igor Bondarenko, Vivek G Nayak, Melody Woods, Matthew A. Hummel, Ashwini Vishweswaramurthy, Gopinath Ranganna, Roxann Shapiro, Katrin Beckmann, Subramanian Loganathan, Tazeen Idris, Anita Rao, Alexander Luft, Abhijit Barve, Charles Donnelly
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: This phase III study compared the efficacy and safety of proposed biosimilar MYL-1402O with reference bevacizumab (BEV), as first-line treatment for patients with stage IV non-squamous non-small-cell lung cancer. Patients and methods: Patien